Disc Medicine
IRON
55 hedge funds and large institutions have $165M invested in Disc Medicine in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 12 closing their positions.
229% more call options, than puts
Call options by funds: $3.48M | Put options by funds: $1.06M
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
12% more funds holding
Funds holding: 49 → 55 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 2% → 1.98% (-0.02%)
52% less capital invested
Capital invested by funds: $347M → $165M (-$181M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$12.1M |
| 2 |
BlackRock
New York
|
+$11.1M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$9.02M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.26M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$11M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.65M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.55M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.44M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$3.29M |
IRON Hedge Fund Activity: Q2 2021 in Review
55 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Disc Medicine (IRON) for Q2 2021, worth a combined $165M — down 52% from $347M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IRON positions and 12 closed out — a net gain of 6 holders — while 17 added to existing stakes and 15 trimmed.
The largest buyer was Franklin Resources, adding an estimated $12.1M. The largest seller was Opaleye Management, exiting entirely with an estimated $11M sold.
- 55 institutional investors held Disc Medicine (IRON) as of Q2 2021, up from 49 in Q1 2021.
- Funds reported $165M of Disc Medicine stock for Q2 2021, down 52% quarter-over-quarter.
- 18 funds opened new Disc Medicine positions in Q2 2021 and 12 closed out, a net change of +6 holders.
- The largest Disc Medicine buyer in Q2 2021 was Franklin Resources, an estimated $12.1M added.
- The largest Disc Medicine seller in Q2 2021 was Opaleye Management, an estimated $11M sold.
Based on aggregated 13F filings for Q2 2021.